Roche Pharmaceutical Development and Sales Overview
Our contribution against COVID-19
Roche has enabled access to >1.8 billion tests to fight the COVID-19 pandemic
Roche
20+ solutions
Broad portfolio of COVID-19
solutions
Selected launches and
acquisitions
Responsible pricing to
enable access
>1.8 billion COVID-19
tests
Conducted with our products
since 2020
Costs should not be a barrier to
access testing
~2'000 cobas® 6800/8800
instruments placed¹
Increase over two-fold since the
pandemic, enabling increased
access to testing beyond COVID-19
1st SARS-CoV-2
detection test (RUO)
Anti-SARS-CoV-2 test
(qual. Ab lab test)
SARS-COV-2 rapid Ag
(POC)
Acquisition of
GenMark Diagnostics
Launch of cobasⓇ
5800
EUA for SARS-COV-2
rapid Ag home test
Elecsys® IGRA
SARS-COV-2
2020
2021
2022
Test
Instrument
Acquisition
cobasⓇ SARS-CoV-2
on cobas® 6800/8800
cobasⓇ Liat SARS-
CoV-2 & Influenza
A/B
Anti-SARS-CoV-2 S
test (quant. Ab lab
test)
New
Antigen Test 2.02
1 cobas® 6800/8800 instruments installed base per September 2022; 2 ElecsysⓇ IGRA SARS-CoV-2 upcoming launch in end of July, 2022; 2 sensitivity of 99.00% (95% CI: 94.55 - 99.97%) and a relative specificity of 99.75%
(95% CI: 98.62 -99.99%); RUO: Research use only; POC: Point of care; EUA: Emergency Use Authorization; Ab: Antibody; Ag: Antigen
Acquisition of
TIB Molbiol
Test to detect
Omicron variant
SARS-CoV-2 Rapid
SARS-COV-2 DUO
38View entire presentation